CMV serostatus is associated with improved survival and delayed toxicity onset following anti-PD-1 checkpoint blockade
Open Access
- 23 April 2025
- journal article
- research article
- Published by Springer Nature in Nature Medicine
- Vol. 31 (7) , 2350-2364
Abstract
Cytomegalovirus (CMV) is a globally endemic latent herpes virus that profoundly impacts T cell immunity. We investigated the oncological consequences of CMV infection across 341 prospectively recruited patients receiving immune checkpoint blockade (ICB) for melanoma. CMV+ patients with metastatic melanoma (MM) have higher lymphocyte counts, reduced neutrophil to lymphocyte ratio and divergent CD8+ T cell gene expression. Combination anti-CTLA-4/anti-PD-1 ICB, but not single-agent anti-PD-1 ICB, induces cytotoxicity and CMV-associated gene expression in CD8+ T cells from CMV− patients. Correspondingly, overall survival was independent of CMV serostatus in combination anti-CTLA-4/anti-PD-1 ICB recipients (CMV+ hazard ratio for death: 1.02, P = 0.92), whereas CMV+ single-agent anti-PD-1 ICB recipients had improved overall survival (CMV+ hazard ratio for death: 0.37, P < 0.01), a finding also seen in CMV+ adjuvant single-agent anti-PD-1 ICB recipients (CMV+ hazard ratio for recurrence: 0.19, P = 0.03). We identify TBX21, encoding T-bet, as a transcriptional driver of CMV-associated CD8+ T cell gene expression, finding that TBX21 expression is predictive of overall survival (hazard ratio: 0.62, P = 0.026). CMV+ patients unexpectedly show reduced cumulative incidence of grade 3+ immune-related adverse events at 6 months (0.30 versus 0.52, P = 2.2 × 10−5), with lower incidence of colitis (P = 7.8 × 10−4) and pneumonitis (P = 0.028), an effect replicated in non-melanoma ICB recipients (n = 58, P = 0.044). Finally, we find reduced CMV seropositivity rates in patients with MM compared with UK Biobank controls (odds ratio: 0.52, P = 1.8 × 10−4), indicating CMV seropositivity may protect against MM. Specifically, patients with BRAF-mutated MM are less likely to be CMV+ (odds ratio = 2.2, P = 0.0054), while CMV− patients present 9 yr earlier with BRAF wild-type MM (P = 1.3 × 10−4). This work reveals an interaction between CMV infection, MM development according to BRAF status and response to ICB, while demonstrating CMV infection is protective against severe ICB immune-related adverse events, highlighting the potential importance of previous infection history and chronic immune activation in MM development and immunotherapy outcomes.Keywords
Funding Information
- Wellcome Trust (226535/Z/22/Z, 222426/Z/21/Z, 226535/Z/22/Z, BST00070, 226535/Z/22/Z, 226535/Z/22/Z, 226535/Z/22/Z, 226535/Z/22/Z, 201488/Z/16/Z, 201488/Z/16/Z, 201488/Z/16/Z, 201488/Z/16/Z, 222426/Z/21/Z, 226535/Z/22/Z, 226535/Z/22/Z)
- Cancer Research UK (DRCNPG-Nov22/100005, DRCNPG-Nov22/100005)
- DH | National Institute for Health Research (Oxford BRC, ACL)
This publication has 84 references indexed in Scilit:
- Cancer risk associated with cytomegalovirus infection among solid organ transplant recipients in the United StatesCancer, 2022
- ‘From immunosenescence to immune modulation’: a re-appraisal of the role of cytomegalovirus as major regulator of human immune functionMedical Microbiology and Immunology, 2019
- Diagnosis and Management of CMV ColitisCurrent Infectious Disease Reports, 2019
- Estimation of the worldwide seroprevalence of cytomegalovirus: A systematic review and meta‐analysisReviews in Medical Virology, 2019
- Safety and Efficacy of Antiviral Therapy for Prevention of Cytomegalovirus Reactivation in Immunocompetent Critically Ill PatientsJAMA Internal Medicine, 2017
- Skin Tumours2017
- Blimp‐1 homolog Hobit identifies effector‐type lymphocytes in humansEuropean Journal of Immunology, 2015
- ATAC‐seq: A Method for Assaying Chromatin Accessibility Genome‐WideCurrent Protocols in Molecular Biology, 2015
- The pathogenesis of human cytomegalovirusThe Journal of Pathology, 2014
- Review of cytomegalovirus seroprevalence and demographic characteristics associated with infectionReviews in Medical Virology, 2010